According to these studies, we found APS could significantly suppress the levels of TGF-β and IL-10 in vivo and in vitro while increasing the levels of IFN-γ, TNF-α, IL-2, and IL-1β, regulating the growth factor VEGF, and reverting the immune-suppressed TME, hopefully to be an adjuvant drug in immunotherapy (Table 2). The gene discussed is IFNG; the disease is autoimmune polyendocrinopathy.